• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


BioReliance Opens New Clearance Services Facility In Rockville, Maryland

Sigma-Aldrich Corporation's BioReliance, a biologics and early-development services business, opened its new Clearance Services facility in Rockville, Maryland.

BioReliance provides contract services that offer more than 1,000 tests and services related to biologics safety testing, specialized toxicology and animal health services. The firm said its Rockville facility features four large clearance suites with modular layouts that allow for customized laboratory setups. The new facility more than doubles the amount of space available to clients to conduct their critical downstream bioprocessing studies.

All studies performed at the facility are secure and supported by dedicated scientists and state-of-the-art chromatography equipment, the company said. Every project is also fully compliant with applicable global guidelines and regulations, including those from the U.S. Food and Drug Administration and European Medicines Agency. The center allows BioReliance to offer increased capacity and flexible scheduling, while maintaining its core focus on providing industry-leading quality, expertise and value.

"Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary Complete Clearance services to our clients. It's all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience," said Archie Cullen, president of BioReliance. "Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products."

Exclusive Research